Innatoss Laboratories

Innatoss Laboratories

Oss, Netherlands· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

Innatoss Laboratories is a Dutch diagnostic company founded in 2014, specializing in challenging infectious diseases like Lyme, Q fever, and COVID-19. Its core strategy involves smartly utilizing or developing new immunological tests to improve diagnostic accuracy and speed, thereby aiming to prevent chronic conditions. The company engages in both commercial testing services and collaborative research with academic and patient organizations, positioning itself as a niche expert in a difficult diagnostic segment.

Infectious Diseases

Technology Platform

Immunology-based diagnostic assay development and validation, including T-cell tests (Q-detect™) and surrogate virus neutralization tests (cPass™).

Funding History

2
Total raised:$5.5M
Seed$3M
Grant$2.5M

Opportunities

Growing awareness and incidence of Lyme disease creates a expanding market for advanced diagnostics.
The need for sophisticated immune monitoring post-COVID-19 vaccination and infection presents a sustained opportunity for their neutralizing antibody tests.
Their research leadership in Q fever could position them as a key partner in future vaccine development and adoption.

Risk Factors

Revenue concentration in a few disease areas and potential decline in COVID-19 testing demand.
Competition from larger diagnostic firms with greater resources.
Regulatory and reimbursement challenges for novel diagnostic criteria in complex diseases like chronic Lyme.

Competitive Landscape

Innatoss competes in niche segments against large commercial labs offering standard serology and specialized university/hospital labs. For Lyme, it faces competition from companies like Zeus Scientific and Euroimmun, but differentiates with a focus on complex cases. In COVID-19 serology, it competes on quality (neutralization assays) rather than volume.